Hyperthermic Intraperitoneal Chemotherapy as a Treatment for Epithelial Ovarian Cancer
- 27 Downloads
Treatment by cytoreductive surgery (CRS) and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has been an option for selected patients with peritoneal carcinomatosis. This study aims to evaluate the impact of HIPEC in epithelial ovarian cancer (EOC). A retrospective observational cohort study including 48 EOC patients treated and followed up between 2012 and 2016. Thirty-seven cases were treated by CRS only, while 11 cases were treated by CRS and HIPEC. The study was performed at National Cancer Institute (NCI)—Cairo University. There was no statistically significant difference regarding overall survival or disease-free survival between the group of EOC patients treated by CRS only and the one treated by CRS and HIPEC. Presence of ascites and histological types (serous/non-serous) were the significant independent variables related to overall survival. Presence of ascites was the only independent variable associated with a significant relation to disease-free survival. No statistically significant impact of HIPEC in treatment of EOC was found in this study.
KeywordsEpithelial ovarian cancer (EOC) Peritoneal carcinomatosis Peritoneal cancer index (PCI) Cytoreductive surgery (CRS) Hyperthermic intraperitoneal chemotherapy (HIPEC)
The study was supported by NCI—Cairo University. NCI played no role in the study design, data collection, data analysis, or manuscript writing. All the authors read and approved the final manuscript.
Compliance with Ethical Standards
The study was approved by the ethical committee of NCI. Clinical data were collected from hospital medical records and investigations’ reports, recorded in a standard database form, evaluated and analyzed by the authors. For this type of study (retrospective study), formal consent is not required.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, González-Gil A, Parrilla JJ, Parrilla P (2014) Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol 21(7):2383–2389. https://doi.org/10.1245/s10434-014-3599-4 CrossRefPubMedGoogle Scholar
- 4.Warschkow R, Tarantino I, Lange J, Müller SA, Schmied BM, Zünd M, Steffen T (2012) Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients. Patient Saf Surg 6(1):12. https://doi.org/10.1186/1754-9493-6-12 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, Asencio JM, Alvarez de Sierra P, Atahualpa Arenas F, Rodriguez del Campo J, Garcia Sabrido JL (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol 39(10):1109–1115. https://doi.org/10.1016/j.ejso.2013.06.022 CrossRefPubMedGoogle Scholar
- 7.Manzanedo I, Pereira F, Pérez-Viejo E, Serrano Á, Hernández-García M, Martínez-Torres B, Rihuete-Caro C, Calzas J, Cueto M (2017) Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Minerva Ginecol 69(2):119–127. https://doi.org/10.23736/S0026-4784.16.03959-9. CrossRefPubMedGoogle Scholar